2025-10-13
2025-10-13
來源:士卓曼官網(wǎng)
上海,2025年9月29日:士卓曼集團(tuán)宣布,集團(tuán)已向南京市中級人民法院提起兩項訴訟,指控北京卡爾斯醫(yī)療器械有限公司及卡爾斯(南京)醫(yī)療器械有限公司專利侵權(quán)及實(shí)施不正當(dāng)競爭行為。兩案均已獲南京市中級人民法院正式受理。
士卓曼集團(tuán)種植事業(yè)部負(fù)責(zé)人安德里亞·烏茨(Andreas Utz)表示:“20多年來,士卓曼始終深耕中國醫(yī)療健康生態(tài)系統(tǒng)。通過近30年持續(xù)投資研發(fā)、本土合作及人才培養(yǎng),我們在推動高質(zhì)量創(chuàng)新、專業(yè)培訓(xùn)及患者護(hù)理等方面做出了巨大貢獻(xiàn)。保護(hù)我們的研發(fā)成果能確保持續(xù)不斷地為全球臨床醫(yī)生和患者提供尖端的解決方案——對于BLX這類創(chuàng)新產(chǎn)品而言,這一點(diǎn)尤為重要。”
展望未來,士卓曼將繼續(xù)全力投入中國市場,擴(kuò)大本土研發(fā)、加強(qiáng)教育項目、深化與本土醫(yī)療健康合作伙伴的關(guān)系。
作為包括士卓曼BLX、TLX在內(nèi)的多項種植體系統(tǒng)的發(fā)明人,奧菲爾·弗羅莫維奇教授( Prof. Dr. Ophir Fromovich ) 表示: “ 保護(hù)知識產(chǎn)權(quán)對支持創(chuàng)新驅(qū)動型市場至關(guān)重要。專利維權(quán)有助于維護(hù)投資者信心、市場穩(wěn)定性和全球合作吸引力。身為種植體系統(tǒng)的發(fā)明人,我深知保護(hù)創(chuàng)新成果的重要性——唯有如此,才能持續(xù)提升患者護(hù)理水平,推動該領(lǐng)域研發(fā)不斷進(jìn)步。”
作為全球牙科解決方案的領(lǐng)導(dǎo)者,士卓曼將因地制宜地向國內(nèi)引入國際標(biāo)準(zhǔn)。集團(tuán)也將致力于通過推動真正創(chuàng)新、培育專業(yè)人才、維護(hù)市場誠信,為中國牙科事業(yè)的未來發(fā)展貢獻(xiàn)力量。
士卓曼集團(tuán)期待繼續(xù)與中國合作伙伴攜手,共同構(gòu)建更加健康、更具創(chuàng)新、更以患者為中心的醫(yī)療體系。
###
About Straumann Group
The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.
Headquartered in Basel, Switzerland, the Group currently employs close to 12 000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.
Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland
Phone: +41 (0)61 965 11 11
Homepage: www.straumann-group.com
Contacts:
Corporate Communication
E-mail: corporate.communication@straumann.com
Investor Relations
E-mail: investor.relations@straumann.com
Disclaimer
This press release contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this document. Accordingly, you should not rely on any forward-looking statements contained in this press release. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this release as of the date it is issued and does not undertake any obligation to update any statements as a result of new information, future events or otherwise.??This release constitutes neither an offer to sell nor a solicitation to buy any securities.
強(qiáng)強(qiáng)聯(lián)手!富士推出首個手持式超高頻3D 超聲設(shè)備
2022-02-28
北美首個臨床訂單,聯(lián)影“史上最強(qiáng)PET/CT”安裝
2022-05-23
德國制造了世界最大醫(yī)療設(shè)備,重670噸四層樓高!
2019-10-30
世界首個白內(nèi)障手術(shù)機(jī)器人,獲3.7億投資
2022-07-27
費(fèi)森尤斯醫(yī)療4008A(TM)血液透析設(shè)備在華上市
2019-09-20
飛利浦新一代圖像引導(dǎo)治療平臺Azurion通過NMPA認(rèn)證在中國正式上市
2019-09-09
評論
請登錄后參與評論...
登錄后參與討論
提交評論